Lack of adverse interactions between concomitantly administered selegiline and citalopram

Clinical Neuropharmacology

Volumn 20, Issue 5, 1997, Pages 419-433

  Laine, Kari ^a   Anttila, Markku ^b   Heinonen, Esa ^b   Helminen, Antti ^a   Huupponen, Risto ^a   Mäki Ikola, Outi ^b   Reinikainen, Kari ^b   Scheinin, Mika ^a  

^a UNIVERSITY OF TURKU   (Finland)

^b ORION CORPORATION   (Finland)

Author keywords

Citalopram; Interaction; Monoamine oxidase; Prolactin; Selegiline; Serotonin

Indexed keywords

3,4 DIHYDROXYPHENYLETHYLENE GLYCOL; 5 HYDROXYINDOLEACETIC ACID; ADRENALIN; ANTIDEPRESSANT AGENT; CITALOPRAM; MONOAMINE OXIDASE INHIBITOR; NORADRENALIN; PLACEBO; PROLACTIN; SELEGILINE; SEROTONIN UPTAKE INHIBITOR;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DEPRESSION; DRUG INDUCED DISEASE; DRUG METABOLISM; HEADACHE; HUMAN; NEUROTOXICITY; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; SEROTONINERGIC SYSTEM; TREATMENT OUTCOME; VERTIGO;

EID: 0030768385     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002826-199710000-00006     Document Type: Article

References (38)

1. Heinonen EH, Rinne UK. Selegiline in the treatment of Parkinson's disease. Acta Neurol Scand 1989;80:103-11.
2. Cummings JL. Depression and Parkinson's disease: a review. Am J Psychiatry 1992;149:443-54.
3. Karasu TB, Docherty JP, Geleberg A. Practice guidelines for major depressive disorder in adults. Am J Psychiatry 1993;150:1-26.
4. Neuvonen PJ, Pohjola-Sintonen S, Tacke U, Vuori E. Five fatal cases of serotonin syndrome after moclobemide-citalopram or moclobemide-clomipramine overdoses. Lancet 1993;342:1419.
5. Taylor D, Duncan D. Moclobemide and SSRIs. Pharm J 1994;253:330.
6. Beasley CM Jr, Masica DN, Heiligenstein JH, Wheadon DE, Zerbe RL. Possible monoamine oxidase inhibitor-serotonin uptake inhibitor interaction: fluoxetine clinical data and preclinical findings. J Clin Psychopharmacol 1993;13:312-20.
7. Sternbach H. The serotonin syndrome. Am J Psychiatry 1991;148:705-13.
8. Nierenberg DW, Semperon M. The central nervous system serotonin syndrome. Clin Pharmacol Ther 1993;53:84-8.
9. Suchowersky O, deVries JD. Interaction of fluoxetine and selegiline. Can J Psychiatry 1990;35:571-2.
10. Montastruc JL, Chamontin B, Senard JM et al. Pseudophaeochromocytoma in parkinsonian patient treated with fluoxetine plus selegiline. Lancet 1993;341:555.
11. Jermain DM, Hughes PL, Follender AB. Potential fluoxetine-selegiline interaction. Ann Pharmacother 1992;26:1300.
12. Waters CH. Fluoxetine and selegiline - lack of significant interaction. Can J Neurol Sci 1994;21:259-61.
13. Richard I, Kurlan R. Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson's disease [Abstract]. Neurology 1996;46(suppl):374.
14. Yu LJ, Zweig RM. Successful combination of selegiline and antidepressants in Parkinson's disease [Ab stract]. Neurology 1996;46(suppl):374.
15. Gram LF, Fluoxetine. N Engl J Med 1994;331:1354-61.
16. Grace JM, Kinter MT, Macdonald TL. Atypical metabolism of deprenyl and its enantiomer, (S)-(+)-N,α-dimethyl-N-propynylphenethylamine, by cytochrome P450 2D6. Chem Res Toxicol 1994;7:286-90.
17. Murphy DL, Sunderland T, Garric NA, Aulakh CS, Cohen RM. Selective amine oxidase inhibitors: basic to clinical studies. In: Dahl SG, Gram LF, Paul SM, Potter WZ, eds. Clinical Pharmacology in Psychiatry. Berlin: Springer-Verlag. 1987:135-46.
18. Milne JR, Goa KL. Citalopram. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness. Drugs 1991;41:450-77.
19. Toyama SC, Iacono RP. Is it safe to combine a selective serotonin reuptake inhibitor with selegiline? Ann Pharmacother 1994;28:405-6.
20. Karnani H. Determination of selegiline and desmethylselegiline in human serum by gas chromatography using nitrogen selective detection. Bioanalytical method report, 1 July 1993, Orion Corporation, Farmos Research.
21. Brooks MA, DiDonato G. Determination of chlorprotixene and its sulfoxide metabolite in plasma by high-performance liquid chromatography with ultraviolet and amperometric detection. J Chromatogr 1985;337:351-62.
22. Scheinin M, Karhuvaara S, Ojala-Karlson P, Kallio A, Koulu M. Plasma 3,4-dihydroxphenylglycol (DHPG) and 3-methoxy-4hydroxyphenyl-glycol (MHPG) are insensitive indicators of alpha-2-adrenoreceptor mediated regulation of norepinephrine release in healthy volunteers. Life Sci 1991;49:75-84.
23. Kwarts E, Kwarts J, Rutgers H. A simple paired-ion liquid chromatography assay for serotonin in cerebrospinal fluid, platelet rich plasma, serum and urine. Ann Clin Biochim 1984;21:425-9.
24. Richards DA, Titheradge AC. Simultaneous liquid chromatographic determination of vanillyImandelic acid, homovanillic acid and 5-hydroxy-3-indoleacetic acid in urine, using isocratic elution and electrochemical detection. Biomed Chromatogr 1987;2:115-9.
25. Chrisp P, Mammen GJ, Sorkin EM. Selegiline. A review of its pharmacology, symptomatic benefits and protective potential in Parkinson's disease. Drugs Aging 1991;1:228-48.
26. Koulu M, Scheinin M, Kaarttinen A, et al. Inhibition ol monamine oxidase by moclobemide: effects on monoamine metabolism and secretion of anterior pituitary hormones and cortisol in healthy volunteers. Br J Clin Pharmacol 1989;27:243-55.
27. Heinonen EH, Anttila MI, Lammintausta RAS. Pharmacokinetic aspects of 1-deprenyl (selegiline) and its metaboliies. Clin Pharmacol Ther 1994;56:742-9.
28. Meltzer HY, Simonovic M, Sturgeon RD, Fang VS. Effect of antidepressants, lithium and electroconvulsive treatment on rat serum prolactin levels. Acta Psychiatr Scand 1981;290(suppl):100-21.
29. Calil HM, Lesieur P, Gold PW, Brown GM, Zavadil AP III, Potter WZ. Hormonal responses to zimelidine and desipramine in depressed patients. Psychiatr Res 1984;13:231-4.
30. Nutt D, Middleton H, Franklin M. The neuroendocrine effects of oral imipramine. Psychoneuroendocrinology 1987;12:367-75.
31. Mendlewicz J, Youdim MBH. Monoamine-oxidase inhibitors and prolactin secretion. Lancet 1977;3:507.
32. Agnoli A, Ruggieri S, Baldassarre M, et al. Presynaptic neuron and postsynaptic dopamine receptor function in long term treatment of Parkinson's disease: a neuroendocrine study. Neurochem Clin Neurol 1980;39:215-24.
33. MohanKumar PS, Meites J, Quadri SK. Deprenyl reduces serum prolactin concentrations in rats. Life Sci 1994;54:841-5.
34. Calabresi P, Silvestrini M, Stratta F, et al. L-deprenyl test in migraine: neuroendocrinological aspects. Cephalalgia 1993;13:406-9.
35. Perenyi A, Bagdy G, Arato M. An early phase II trial with L-deprenyl for the treatment of neurolepticinduced parkinsonism. Pharmacopysychiatria 1983;16:143-6.
36. Hyttel J. Pharmacological characterization of selective serotonin uptake inhibitors (SSRIs). Int Clin Psychopharmacol 1994;9(suppl 1):19-26.
37. Heinonen EH, Myllvlä V, Sotaniemi K, et al. Pharmacokinetics and metabolism of selegiline. Acta Neurol Scand 1989;80:93-9.
38. Borbe HO, Niebch G, Nickel B. Kinetic evaluation of MAO-B-activity following oral administration of selegiline and desmethyl-selegiline in rat. J Neural Transm 1990;32:131-7.